Methods for detecting phosphorylated alpha-synuclein
AssigneeProthena Biosciences Limited
InventorsRobin Barbour, Lynn R. Zieske, Sarah Hamren
Life of this patent
Estimating the term…
Abstract
The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.
Claims38
A method of detecting alpha-synuclein phosphorylated at serine 129 (PS129 alpha-synuclein), comprising:
- (a) contacting a sample with a capture antibody that preferentially binds to PS129 alpha-synuclein and a reporter antibody that specifically binds to an epitope within residues 40-55 of alpha-synuclein, wherein the capture antibody comprises the Kabat CDRs of 11A5 (ATCC accession number PTA-8222) and the reporter antibody comprises the Kabat CDRs of 23E8 (ATCC accession number PTA-122711);
- wherein if PS129 alpha-synuclein is present in the sample, the capture antibody and reporter antibody bind to the PS129 alpha-synuclein forming a sandwich complex;
- and
- (b) detecting the reporter antibody that binds to the PS129 alpha-synuclein in step (a), if any, to indicate presence or absence of the PS129 alpha-synuclein.
A monoclonal antibody comprising the Kabat CDRs of 23E8 (ATCC accession number PTA-122711).
Dependencies are inferred from the claim text.